Niel, September 24th, 2012 – Multiplicom, a molecular diagnostics company specializing in innovative molecular genetics tests based on massively parallel sequencing (MPS) today announces that it is launching new genomic and somatic mutation detection kits based on its proprietary MASTR technology.
The genomic kits enable PCR amplification of all coding regions of genes known to cause Mucovisidosis, Marfan syndrome, Alport syndrome, Polycystic Kidney Disease, Familial Mediterranean Fever and Duchenne Muscular Dystrophy through the identification of single nucleotide polymorphisms, small deletions/insertions and copy number variations. The EGFR MASTR kit is Multiplicom’s first somatic mutation detection product for the analysis of tumour tissue, targeting exons 18 to 21 of the EGFR gene, key to selecting the most effective treatment options.
These newly launched tests complement Multiplicom’s MASTR product line which can be used in combination with all benchtop MPS instruments. Earlier this month, Multiplicom started shipping BRCA MASTR Dx, its first CE/IVD labelled kit, and is in the process of qualifying other kits for EU regulatory approval.
Dr Dirk Pollet, CEO of Multiplicom, said: “The introduction of the new kits establishes Multiplicom as a European leader in the implementation of MPS in routine diagnostic labs. Multiplicom’s products are simple, easy to use, only require standard equipment and are compatible with MPS equipment from Roche, Life Technologies and Illumina.”
For more information please contact:
Dr Dirk Pollet, CEO
+32 (0) 3 289 14 00
College Hill Life Sciences (PR agency for Multiplicom)
Stefanie Bacher / Henry Stanley
+44 (0) 207 457 2020
Multiplicom produces molecular diagnostic kits that enable clinical laboratories to perform affordable testing for personalized medicine. The Company was created in 2011 as a spin-off by the University of Antwerp and VIB. Multiplicom develops, manufactures and commercializes leading-edge and easy-to-use genetic test kits based on the latest molecular diagnostic technologies. The successful introduction of its kits in medical genetics labs proves they are the solution to an increasing demand for nucleic acid based testing that is driven by the scientific evidence that links genetic information to health and disease. For further information please visit www.multiplicom.com